Redenlab
measuring speech

What we do

Speech is a sensitive biomarker for guiding decision-making in clinical trials, health research & workforce monitoring

 

Clinical trials

Our speech tests are valid, quick and reliable, with demonstrated sensitivity to subtle disease or treatment induced change

 

Academic & health research

Speech tests and analysis solutions for academic collaborations and public-private engagement

 

recording solutions

Speech software and hardware solutions capable of meeting regulatory requirements for security and integrity of data in clinical trials, including 21 CFR Part 11 and HIPAA

 
0
0
 

Driving innovation in speech biomarker research

•Exploring large clinical datasets using a supervised statistical machine learning framework

•State of the art signal processing algorithms combined with solid acoustic analysis procedures with known stability, reliability and sensitivity

•Clinical expertise in a variety of conditions/diseases with access to collaborative network of clinical institutions in USA, Europe & Australia

•Platform for standardization of data collection and worldwide deployment

 
 

Our collaborators and clients

REDENLAB_IMAGE01_2500x850.02.jpg

UPDATES

 

REDENLAB TWEETS

 
 
 

REDENLAB NEWS

Featured
Motor speech and non-motor language endophenotypes of Parkinson’s disease

Article highlights

  • Dysarthria, a neuromuscular speech disorder, can be the first and most prominent manifestation of PD.

  • Alongside changes in speech, PD is associated with impaired morphosyntactic, lexical-semantic, and high-level language comprehension and production.

  • Pharmaceutical and surgical interventions for PD may improve certain modalities of speech production, but effects vary between individuals.

  • Longitudinal research designs are needed to evaluate the complex interplay between motor speech, language, and cognition.

  • Speech acoustics may serve as a valuable proxy marker of PD ‘risk’, disease progression and treatment efficacy.

Read More →
Speech in prodromal and symptomatic Huntington’s disease as a model of measuring onset and progression in dominantly inherited neurodegenerative diseases

Highlights

•Subtle but apparently genuine changes in speech occur in HD before clinical diagnosis.

•Speech changes in prodromal individuals are largely characterised by timing deficits.

•Limited longitudinal data restricts capacity to predict HD evolution using speech.

Read More →
 
 

TAILORED CONSULTANCY SERVICES

Can't find what you're looking for? Get in touch and our team will assist you. We offer specialized services & consultancy tailored for individual projects.